Four Million EU Voters Sign Call Against Upload Filters, Protection Of ‘Snippets’ 13/12/2018 by Monika Ermert for Intellectual Property Watch Leave a Comment Ahead of the 5th trilogue meeting on the future copyright regulation between the rapporteurs of the European Parliament, member states and the European Commission on 13 December in Strasbourg, France, copyright activists collected over 4 million signatories to a petition to amend the draft legislation. Meanwhile, a court decision in Germany today puts use of its auxiliary copyright law for press publishers in question.
Indigenous Knowledge Misappropriation: The Case Of The Zia Sun Symbol Explained At WIPO 11/12/2018 by Catherine Saez, Intellectual Property Watch 1 Comment In 1925, New Mexico, which gained statehood in the United States in 1912, adopted a design for its flag featuring a sun symbol belonging to the Zia peoples. According to the tribe, the symbol was secret and stolen from the Zia, who lost both ownership and control over it, and were left to contemplate the sun symbol being widely used and sometimes desecrated.
EU Members Push For Private Censorship Of Terrorist Content On The Internet 06/12/2018 by Monika Ermert for Intellectual Property Watch 2 Comments Big platform providers and small hosters alike shall be obliged to censor, according to a draft regulation presented by the European Commission in mid-September and accepted by EU member states at their Council meeting today.
Health Advocacy Groups Appeal EPO Decision To Uphold Gilead Hepatitis C Patent 05/12/2018 by Intellectual Property Watch Leave a Comment Six organisations, including Médecins Sans Frontières (MSF, Doctors Without Borders), today appealed a European Patent Office decision to uphold Gilead Science’s patent on hepatitis C drug sofosbuvir.
Study Finds Arthritis Drug Enbrel Overpatented, Overpriced in US 04/12/2018 by Intellectual Property Watch Leave a Comment Initiative for Medicines, Access & Knowledge (I-MAK) released a new study yesterday showing that the rheumatoid arthritis drug Enbrel has been overpatented by drugmaker Amgen, which has filed a total of 57 patents on the drug in the United States. Together, these patents were said to delay market competition by 39 years, rather than the standard 20 years for one patent. The study found that this market exclusivity for Enbrel resulted in US$ 8 billion dollars in sales in 2017 alone.
Gene Editing: Fears Lead To Call For Moratorium At CBD, Discussions Ongoing 23/11/2018 by Catherine Saez, Intellectual Property Watch 2 Comments Gene editing techniques have opened the way to a new world of innovations. One of them is the potential eradication of malaria-carrying mosquitoes. What appears as a very attractive way to help with malaria eradication is denounced by civil society groups arguing that the technology is in its infancy. Wiping out entire species could have unforeseen environmental, health, and social consequences, they say. They are calling for a moratorium preventing the release of gene drive organisms in the wild. They also describe the gene drive mosquitoes as a Trojan horse, hiding broader interests of agricultural multinational corporations.
UN Committee Adopts ‘Landmark’ Declaration Reinforcing Peasants’ Rights To Seeds 23/11/2018 by Catherine Saez, Intellectual Property Watch 1 Comment The social, humanitarian and cultural committee of the United Nations meeting this month adopted a UN Declaration on the Rights of Peasants and Other People Working in Rural Areas. The declaration includes the right to save, exchange, and sell farm-saved seeds, a contentious issue for which small farmers have been campaigning for years.
African Civil Society Outcry Over ARIPO’s Closed Decision-Making On Health And IP 22/11/2018 by Intellectual Property Watch 1 Comment As the African Regional Intellectual Property Organization (ARIPO) Administrative Council meets this week, more than 60 civil society groups are calling for greater inclusion and more transparency on access to medicines and diagnostics. Signatories are asking for a review of the Harare Protocol on patents and industrial designs, and raised concern about over-reliance on advice of the United Nations intellectual property agency for decisions affecting broader public health in the region.
Key Hepatitis C Drug Licensed To Medicines Patent Pool, Access Expanded For LMICs 12/11/2018 by David Branigan, Intellectual Property Watch 2 Comments A key drug to treat hepatitis C has been licensed to the Medicines Patent Pool, enabling generic production and expanding affordable access to the drug in low and middle-income countries, excluding the very largest. The agreement between the Pool and AbbVie had been over a year in the making, MPP Executive Director Charles Gore told Intellectual Property Watch.
Report Finds “Overpatenting”, Overpricing Of Top Diabetes Drug In US 05/11/2018 by David Branigan, Intellectual Property Watch Leave a Comment Non-profit patent researchers studying the most prominent prescription insulin drug to treat diabetes in the United States found it is “overpatented” and “overpriced,” enabling unwarranted price-hikes resulting in rising costs for patients and taxpayers.
